Assure yourself with latest market data through free annual update of Coronavirus Outbreak and Chronic Disease Management Market report. Get in touch with the sales team to know more about the covid update package.
ID: MRFR/HS/0475-HCR | February 2021 | Region: Global | 90 pages
Impact of COVID- 19 on Chronic Disease Management Market
The impact of COVID-19 on the economy will affect not just people’s income but also their health. A team from the Northwell Health COVID-19 Research Consortium and the Feinstein Institutes for Medical Research collected data on the patients from the enterprise EHR reporting database. In the largest study of hospitalized COVID-19 patients in the US, researchers leveraged EHR data to find that hypertension, diabetes, and obesity are key chronic diseases in the acuity of the virus. Researchers found that of the 2,634 patients studied, 56.6 percent had hypertension, 41.7 percent had obesity, and 33.8 percent had diabetes – the most common comorbidities among the research subjects.
Source: Northwell Health COVID-19 Research Consortium, the Feinstein Institutes for Medical Research, MRFR Analysis
According to the Department of Health and Social Care, in England, the treatment and care of people with chronic diseases account for an estimated 70% of total health and social care expenditure. Around one in three of the population currently have at least one long-term health condition. Currently, most of the resources and expenditures are allocated for the mitigation of the pandemic. This is expected to delay the treatment of patients suffering from chronic diseases.
India accounts for approximately one-quarter of the world’s TB burden, with the estimated number of new TB cases in 2018 at 2,800,000. To curb the spread of COVID-19, the Indian Government announced a nationwide lockdown in March 2020. The lockdown is a major hurdle to TB patients seeking health care and may result in a delay in diagnosis, treatment interruptions, and disease transmission in household contacts. Lockdown has also forced many migrant workers to return to their homes, leading to treatment interruption. Many health facilities are turning to the use of digital platforms to make medical care accessible in difficult to reach areas. To eliminate TB by 2025, a greater number of pharmaceutical companies will need to work in congruence with healthcare providers. A study published by researchers at two universities in Taiwan and the Johns Hopkins Bloomberg School of Public Health following the 2002-2004 SARS outbreak suggested that chronic-care hospitalizations for diabetes plummeted during the crisis but skyrocketed afterward. Health experts are worried that similar problems could crop up because of the Covid-19 pandemic.
During Italy's national lockdown for COVID-19, official hospital statistics in the period March 1–27, 2020, showed substantial decrease—ranging from 73% to 88%—in pediatric emergency department visits compared with the same time in 2019 and 2018. The fall in the number of visits to pediatric emergency departments across five hospitals in Italy.
Source: The Lancet, MRFR Analysis
Startups are pushing to educate people with chronic conditions about COVID-19.
Clover is using an algorithm to pinpoint the patients most at risk of infection. Clover’s clinicians are using that to reach out to certain patients and suggest patients avoid places where they would be likely to be exposed to infection
Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porterβs Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
β
6. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION
6.1. Overview
6.2. Educational Solution
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
6.3. Implementation Solution
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
6.4. Consulting Solution
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
6.5. Others
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
7. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE
7.1. Overview
7.2. Cloud-Based
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
7.3. On-Premises
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
7.4. Web Based
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION
8.1. Overview
8.2. Arthritis
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.3. Cardiovascular Disease
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.4. Cancer
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.5. Diabetes
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.6. Others
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
9. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END-USER
9.1. Overview
9.2. Providers
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
9.3. Payers
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
10. GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION
10.1. Overview
10.2. Americas
10.2.1. North America
10.2.1.1. US
10.2.1.2. Canada
10.2.2. Latin America
10.3. Europe
10.3.1. Western Europe
10.3.1.1. Germany
10.3.1.2. France
10.3.1.3. Italy
10.3.1.4. Spain
10.3.1.5. UK
10.3.1.6. Rest of Western Europe
10.3.2. Eastern Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle East & Africa
10.5.1. Middle East
10.5.2. Africa
11. COMPANY LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Chronic Disease Management Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Chronic Disease Management Market
11.7. Key developments and Growth Strategies
11.7.1. DELIVERY MODE Launch/ Deployment
11.7.2. Mergers and Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix & Market Ratio
11.8.1. Sales & Operating Income 2020
11.8.2. Major Players R&D Expenditure 2020
11.9. Major Players Capital Market Ratio
12. COMPANY PROFILES
12.1. TriZetto Corporation
12.1.1. Company Overview
12.1.2. Product Overview
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Infosys Limited
12.2.1. Company Overview
12.2.2. Product Overview
12.2.3. Financial Overview
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Pegasystems Inc.
12.3.1. Company Overview
12.3.2. Product Overview
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Siemens Healthcare Private Limited
12.4.1. Company Overview
12.4.2. Product Overview
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. MINES & Associates, Inc.
12.5.1. Company Overview
12.5.2. Product Overview
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Allscripts Healthcare Solutions, Inc.
12.6.1. Company Overview
12.6.2. Product Overview
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Koninklijke Philips NV
12.7.1. Company Overview
12.7.2. Product Overview
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. EXL Healthcare
12.8.1. Company Overview
12.8.2. Product Overview
12.8.3. Financial Overview
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Harmony Information Systems, Inc.
12.9.1. Company Overview
12.9.2. Product Overview
12.9.3. Financial Overview
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. ScienceSoft USA Corporation. (US)
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SYNOPSIS, 2020β2027
TABLE 2 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET ESTIMATES & FORECAST, 2020β2027 (USD MILLION)
TABLE 3 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET, BY REGION, 2020β2027 (USD MILLION)
TABLE 8 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 9 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 10 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 11 NORTH AMERICA CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 12 US: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 13 US: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 14 US: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 15 US: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 16 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 17 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 18 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 19 CANADA: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 20 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 21 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 22 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 23 LATIN AMERICA: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 24 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 25 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 26 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 27 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 28 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 29 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 30 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 31 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 32 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 33 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 34 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 35 EASTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 36 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 37 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 38 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 39 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY SOLUTION, 2020β2027 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY DELIVERY MODE, 2020β2027 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY APPLICATION, 2020β2027 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET, BY END USER, 2020β2027 (USD MILLION) β
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHRONIC DISEASE MANAGEMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHRONIC DISEASE MANAGEMENT MARKET
FIGURE 4 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY SOLUTION, 2020 (%)
FIGURE 5 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY DELIVERY MODE, 2020 (%)
FIGURE 6 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY APPLICATION, 2020 (%)
FIGURE 7 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY END USER, 2020 (%)
FIGURE 8 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 AMERICAS: CHRONIC DISEASE MANAGEMENT MARKET SHARE BY REGION, 2020 (%)
FIGURE 10 NORTH AMERICA: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 EUROPE: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY REGION, 2020 (%)
FIGURE 12 WESTERN EUROPE: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 ASIA-PACIFIC: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 MIDDLE EAST & AFRICA: CHRONIC DISEASE MANAGEMENT MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 15 GLOBAL CHRONIC DISEASE MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 16 TRIZETTO CORPORATION: KEY FINANCIALS
FIGURE 17 TRIZETTO CORPORATION: SEGMENTAL REVENUE
FIGURE 18 TRIZETTO CORPORATION: REGIONAL REVENUE
FIGURE 19 INFOSYS LIMITED: KEY FINANCIALS
FIGURE 20 INFOSYS LIMITED: SEGMENTAL REVENUE
FIGURE 21 INFOSYS LIMITED: REGIONAL REVENUE
FIGURE 22 PEGASYSTEMS INC.: KEY FINANCIALS
FIGURE 23 PEGASYSTEMS INC.: SEGMENTAL REVENUE
FIGURE 24 PEGASYSTEMS INC.: REGIONAL REVENUE
FIGURE 25 SIEMENS HEALTHCARE: KEY FINANCIALS
FIGURE 26 SIEMENS HEALTHCARE: SEGMENTAL REVENUE
FIGURE 27 SIEMENS HEALTHCARE: REGIONAL REVENUE
FIGURE 28 KONINKLIJKE PHILIPS N.V.: KEY FINANCIALS
FIGURE 29 KONINKLIJKE PHILIPS N.V.: SEGMENTAL REVENUE
FIGURE 30 KONINKLIJKE PHILIPS N.V.: REGIONAL REVENUE
FIGURE 31 EXL HEALTHCARE: KEY FINANCIALS
FIGURE 32 EXL HEALTHCARE: SEGMENTAL REVENUE
FIGURE 33 EXL HEALTHCARE: REGIONAL REVENUE
FIGURE 34 HARMONY INFORMATION SYSTEMS, INC.: KEY FINANCIALS
FIGURE 35 HARMONY INFORMATION SYSTEMS, INC.: SEGMENTAL REVENUE
FIGURE 36 HARMONY INFORMATION SYSTEMS, INC.: REGIONAL REVENUE
FIGURE 37 SCIENCESOFT USA CORPORATION.: KEY FINANCIALS
FIGURE 38 SCIENCESOFT USA CORPORATION.: SEGMENTAL REVENUE
FIGURE 39 SCIENCESOFT USA CORPORATION.: REGIONAL REVENUE